160 related articles for article (PubMed ID: 10959214)
1. Prostatic steroid 5 alpha-reductase, an androgen metabolic gene.
Reichardt JK
Mayo Clin Proc; 2000 Jan; 75 Suppl():S36-9. PubMed ID: 10959214
[TBL] [Abstract][Full Text] [Related]
2. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA.
Makridakis NM; Ross RK; Pike MC; Crocitto LE; Kolonel LN; Pearce CL; Henderson BE; Reichardt JK
Lancet; 1999 Sep; 354(9183):975-8. PubMed ID: 10501358
[TBL] [Abstract][Full Text] [Related]
3. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk.
Reichardt JK; Makridakis N; Henderson BE; Yu MC; Pike MC; Ross RK
Cancer Res; 1995 Sep; 55(18):3973-5. PubMed ID: 7664265
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
Lunn RM; Bell DA; Mohler JL; Taylor JA
Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
[TBL] [Abstract][Full Text] [Related]
5. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase.
Makridakis N; Ross RK; Pike MC; Chang L; Stanczyk FZ; Kolonel LN; Shi CY; Yu MC; Henderson BE; Reichardt JK
Cancer Res; 1997 Mar; 57(6):1020-2. PubMed ID: 9067262
[TBL] [Abstract][Full Text] [Related]
6. GEN GEN: the genomic genetic analysis of androgen-metabolic genes and prostate cancer as a paradigm for the dissection of complex phenotypes.
Reichardt JK
Front Biosci; 1999 Jul; 4():D596-600. PubMed ID: 10417059
[TBL] [Abstract][Full Text] [Related]
7. Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort.
Cheng I; Penney KL; Stram DO; Le Marchand L; Giorgi E; Haiman CA; Kolonel LN; Pike M; Hirschhorn J; Henderson BE; Freedman ML
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1993-7. PubMed ID: 17035411
[TBL] [Abstract][Full Text] [Related]
8. A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer: a case-control analysis.
Kantoff PW; Febbo PG; Giovannucci E; Krithivas K; Dahl DM; Chang G; Hennekens CH; Brown M; Stampfer MJ
Cancer Epidemiol Biomarkers Prev; 1997 Mar; 6(3):189-92. PubMed ID: 9138662
[TBL] [Abstract][Full Text] [Related]
9. VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men.
Torkko KC; van Bokhoven A; Mai P; Beuten J; Balic I; Byers TE; Hokanson JE; Norris JM; Barón AE; Lucia MS; Thompson IM; Leach RJ
Clin Cancer Res; 2008 May; 14(10):3223-9. PubMed ID: 18483391
[TBL] [Abstract][Full Text] [Related]
10. No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.
Pearce CL; Van Den Berg DJ; Makridakis N; Reichardt JK; Ross RK; Pike MC; Kolonel LN; Henderson BE
Hum Mol Genet; 2008 Aug; 17(16):2456-61. PubMed ID: 18469342
[TBL] [Abstract][Full Text] [Related]
11. Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer.
Lévesque É; Laverdière I; Lacombe L; Caron P; Rouleau M; Turcotte V; Têtu B; Fradet Y; Guillemette C
Clin Cancer Res; 2014 Feb; 20(3):576-84. PubMed ID: 24277450
[TBL] [Abstract][Full Text] [Related]
12. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men.
Platz EA; Pollak MN; Rimm EB; Majeed N; Tao Y; Willett WC; Giovannucci E
Cancer Epidemiol Biomarkers Prev; 1999 Dec; 8(12):1107-10. PubMed ID: 10613344
[TBL] [Abstract][Full Text] [Related]
13. IGF1 genotype, mean plasma level and breast cancer risk in the Hawaii/Los Angeles multiethnic cohort.
DeLellis K; Ingles S; Kolonel L; McKean-Cowdin R; Henderson B; Stanczyk F; Probst-Hensch NM
Br J Cancer; 2003 Jan; 88(2):277-82. PubMed ID: 12610514
[TBL] [Abstract][Full Text] [Related]
14. Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort.
Haiman CA; Garcia RR; Hsu C; Xia L; Ha H; Sheng X; Le Marchand L; Kolonel LN; Henderson BE; Stallcup MR; Greene GL; Press MF
BMC Cancer; 2009 Jan; 9():43. PubMed ID: 19183483
[TBL] [Abstract][Full Text] [Related]
15. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.
Neslund-Dudas C; Bock CH; Monaghan K; Nock NL; Yang JJ; Rundle A; Tang D; Rybicki BA
Prostate; 2007 Nov; 67(15):1654-63. PubMed ID: 17823934
[TBL] [Abstract][Full Text] [Related]
16. D1S80 population data in African Americans, Caucasians, southeastern Hispanics, southwestern Hispanics, and Orientals.
Budowle B; Baechtel FS; Smerick JB; Presley KW; Giusti AM; Parsons G; Alevy MC; Chakraborty R
J Forensic Sci; 1995 Jan; 40(1):38-44. PubMed ID: 7876800
[TBL] [Abstract][Full Text] [Related]
17. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
Allen NE; Forrest MS; Key TJ
Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
[TBL] [Abstract][Full Text] [Related]
18. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4.
Zeigler-Johnson CM; Walker AH; Mancke B; Spangler E; Jalloh M; McBride S; Deitz A; Malkowicz SB; Ofori-Adjei D; Gueye SM; Rebbeck TR
Hum Hered; 2002; 54(1):13-21. PubMed ID: 12446983
[TBL] [Abstract][Full Text] [Related]
19. Generalizability of associations from prostate cancer genome-wide association studies in multiple populations.
Waters KM; Le Marchand L; Kolonel LN; Monroe KR; Stram DO; Henderson BE; Haiman CA
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1285-9. PubMed ID: 19318432
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in genes regulating androgen activity among prostate cancer low-risk Inuit men and high-risk Scandinavians.
Giwercman C; Giwercman A; Pedersen HS; Toft G; Lundin K; Bonde JP; Lundberg Giwercman Y
Int J Androl; 2008 Feb; 31(1):25-30. PubMed ID: 17376218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
